Emergent Biosolutions AI Stock Analysis
Want to see EBS full AI Analyst Report?
Emergent Biosolutions (EBS) AI Stock Analysis
Emergent Biosolutions
(NYSE:EBS)
The score reflects a tug-of-war between strong recent cash generation and improving cost actions (including gross margin guidance improvement and restructuring savings) versus weak profitability and declining revenue, elevated leverage, and bearish technical signals with the stock trading below all key moving averages.
Emergent Biosolutions (EBS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $297.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.13M
- Price to Earnings (P/E)
- -1.1
- Beta (1Y)
- 1.94
- Revenue Growth
- -17.72%
- EPS Growth
- -456.60%
- Country
- US
- Employees
- 900
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Emergent Biosolutions Business Overview & Revenue Model
Company Description
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and natu...
How the Company Makes Money
EBS generates revenue primarily through (1) product sales and procurement contracts and (2) contract services. Product-related revenue is largely driven by medical countermeasures purchased under government procurement and preparedness programs (e.g....
Emergent Biosolutions Earnings Call Summary
The call was generally positive, emphasizing strong year-to-date cash generation, debt reduction, cost-management actions, international MCM diversification, continued naloxone market leadership and progress on growth programs. These positives were tempered by a substantial year-over-year third-quarter revenue decline, negative quarterly adjusted EBITDA, competitive pricing and volume pressure in naloxone, an expected full-year MCM revenue decline and uncertainty around the timing of government and international deliveries.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Emergent now expects full year 2026 total revenues of $600 million to $645 million; MCM revenues are expected to decline versus the prior year based on the timing of remaining international MCM deliveries and U.S. government procurement, while Commercial revenue is currently tracking towards the lower end of the 20% to 25% range of revenue reduction versus 2025. The company expects adjusted gross margin of 45% to 47%, a 300 basis point improvement versus its August guidance, and adjusted EBITDA of $110 million to $140 million, with the upper end of the range consistent with the midpoint of its prior guidance. Restructuring actions are expected to generate approximately $40 million of annualized savings, with the initial impact becoming evident in the fourth quarter of 2026; some orders internationally and with the U.S. government may materialize this year or in the early part of next year.
Emergent Biosolutions Financial Statement Overview
Summary
Fundamentals are mixed: cash flow is a clear strength (TTM operating cash flow about $200M and free cash flow about $188M), but profitability and sales trends are weak (TTM swung back to meaningful losses and revenue declined about 15.7%). Leverage is elevated (debt-to-equity ~1.62), which increases risk if profitability does not stabilize.
Income Statement
28NegativeBalance Sheet
46NeutralCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 649.10M | 742.90M | 1.04B | 1.05B | 1.12B | 1.77B |
| Gross Profit | 270.00M | 350.60M | 375.40M | 360.00M | 473.00M | 793.20M |
| EBITDA | -117.20M | 237.90M | 56.60M | -43.00M | 34.00M | 509.80M |
| Net Income | -260.70M | 52.60M | -190.60M | -760.50M | -211.60M | 219.50M |
Balance Sheet | ||||||
| Total Assets | 995.20M | 1.32B | 1.39B | 1.82B | 3.17B | 2.96B |
| Cash, Cash Equivalents and Short-Term Investments | 175.70M | 205.40M | 99.50M | 111.70M | 642.60M | 576.30M |
| Total Debt | 507.70M | 572.10M | 676.10M | 860.20M | 1.43B | 871.00M |
| Total Liabilities | 682.00M | 796.00M | 906.90M | 1.17B | 1.78B | 1.35B |
| Stockholders Equity | 313.20M | 522.60M | 482.80M | 649.30M | 1.39B | 1.61B |
Cash Flow | ||||||
| Free Cash Flow | 188.40M | 156.80M | 35.80M | -257.90M | -149.90M | 96.10M |
| Operating Cash Flow | 200.10M | 170.60M | 58.70M | -206.30M | -34.10M | 321.10M |
| Investing Cash Flow | -54.00M | 69.40M | 125.20M | 212.30M | -381.30M | -225.00M |
| Financing Cash Flow | -218.40M | -136.60M | -190.00M | -535.70M | 481.20M | -141.00M |
Emergent Biosolutions Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Negative. The current price of 5.79 is below the 20-day moving average (MA) of 6.29, below the 50-day MA of 6.50, and below the 200-day MA of 7.73, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 38.29 is Neutral, neither overbought nor oversold. The STOCH value of 22.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EBS.
Emergent Biosolutions Risk Analysis
Emergent Biosolutions disclosed 59 risk factors in its most recent earnings report. Emergent Biosolutions reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksEmergent Biosolutions Peers Comparison
Overall Rating
AMPH77Outperform
CPIX53Neutral
EBS52Neutral
EVO50Neutral
SIGA49Neutral
TLPH49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $1.25B | 13.05 | 12.59% | ― | 3.11% | -4.26% | |
| 53Neutral | $88.10M | 1.28 | 202.58% | 23.57% | -39.11% | -241.27% | |
| 52Neutral | $297.69M | -1.15 | -61.33% | ― | -17.72% | -456.60% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $580.87M | -2.91 | -25.63% | ― | 0.31% | -19.37% | |
| 49Neutral | $196.88M | 428.12 | 0.42% | ― | -69.60% | -99.10% | |
| 49Neutral | $47.07M | -3.50 | -96.70% | ― | -100.00% | 46.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EBS | Emergent Biosolutions | 5.79 | -4.31 | -42.67% | |
| TLPH | Talphera, Inc. | 0.91 | -0.41 | -31.36% | |
| SIGA | Siga Technologies | 2.74 | -2.48 | -47.50% | |
| AMPH | Amphastar Pharmaceuticals Inc | 29.37 | 3.35 | 12.87% | |
| EVO | Evotec Ag (Adr) | 1.58 | -1.38 | -46.62% | |
| CPIX | Cumberland Pharmaceuticals Inc. | 5.88 | 4.41 | 299.19% |
Emergent Biosolutions Corporate Events
Emergent BioSolutions Secures $22.3 Million Anthrax Vaccine Contract Modification
PositiveOn November 4, 2026, Emergent BioSolutions announced a modification valued at up to $22.3 million under an existing U.S. government contract to supply BioThrax anthrax vaccine. The order supports pre-exposure protection for service members across all...
Emergent BioSolutions Reports Third-Quarter 2026 Results and Restructuring
NegativeEmergent BioSolutions, a biodefense and medical-countermeasures company with a portfolio spanning naloxone, anthrax and smallpox products, reported third-quarter 2026 results on Nov. 2, 2026. Revenue for the quarter ended Sept. 30 was $110.0 million,...
Emergent BioSolutions Announces CFO Transition Amid Transformation
NeutralEmergent BioSolutions announced on October 16, 2026, that longtime chief financial officer Richard S. Lindahl will retire from his role on December 31, 2026, after nearly nine years at the company. He will stay on as a senior executive advisor throug...
Emergent Biosolutions Highlights Global Public Health Countermeasures
PositiveOn September 14, 2026, Emergent BioSolutions’ president and chief executive officer Joseph C. Papa presented at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting the company’s leadership in combating public health threats wor...
Emergent BioSolutions Secures New BARDA Anthrax Contract
PositiveEmergent BioSolutions, a biopharmaceutical company specializing in biodefense and medical countermeasures, has reinforced its position as a key supplier to the U.S. government’s preparedness programs. Its anthrax vaccines CYFENDUS and BioThrax are ap...
Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts
NegativeOn August 5, 2026, Emergent BioSolutions reported second-quarter 2026 revenue of $234.3 million, up 66% year-on-year, alongside a net loss of $180.2 million driven largely by a $191.3 million non-cash impairment charge, while adjusted net income rose...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
